<DOC>
	<DOCNO>NCT01730677</DOCNO>
	<brief_summary>The investigator address clinical efficacy continue lapatinib treatment combine vinorelbine progression trastuzumab lapatinib treatment compare vinorelbine alone HER2 positive metastatic breast cancer patient .</brief_summary>
	<brief_title>Lapatinib+Vinorelbine v Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab</brief_title>
	<detailed_description>This study multicenter , randomize , open label , phase II study . Patients randomize either lapatinib plus vinorelbine ( LV ) arm vinorelbine alone ( V ) arm , satisfied inclusion exclusion criterion . The stratification factor following : 1 ) visceral metastasis vs. others , 2 ) previous response lapatinib treatment , complete response ( CR ) +partial response ( PR ) vs. stable disease ( SD ) ≥ 12wks . Patients LV arm receive daily lapatinib 1,000mg vinorelbine 20mg/m2 day1 day 8 . Patients V arm receive vinorelbine 30mg/m2 day 1 day 8 . Treatment repeat every 21 day unless evidence disease progression unacceptable toxicity noncompliance patient protocol requirement . Response document physical examination , chest abdomen CT prior treatment baseline , every 2 cycle ( window period ± 1 week ) start treatment 18 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Confirmed stage IV recurrent breast cancer Documented HER2 status positive HER2 tumor cell immunohistochemistry ( 3+ ) FISH ( The result SISH CISH also allow ) Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Age ≥ 20 year Measurable evaluable disease accord Response Evaluation Criteria Solid Tumors version 1.1 Patients treat anthracycline base regimen adjuvant/neoadjuvant metastatic setting . Patients experience disease progression treatment lapatinib contain regimen whose response stable disease ( include CR , PR , SD≥ 12 week ) treatment . There limitation time interval stop lapatinib treatment study enrollment . Patients must receive 2 3 line prior antiHER2 therapy metastatic setting follow regardless order In case trastuzumab : monotherapy combine taxane combine AI In case lapatinib : monotherapy combine capecitabine combine AI Patients receive TDM1 pertuzumab trastuzumab previously allow study Patients receive neratinib , mTOR inhibitor , PI3K/AKT inhibitor , BIBW2992 eligible Patients experience disease recurrence receive adjuvant trastuzumab within 6 month completion adjuvant trastuzumab treatment allow even patient receive trastuzumab metastatic setting . Patients experience disease recurrence receive adjuvant lapatinib within 6 month completion adjuvant lapatinib treatment allow long meet criterion CR , PR SD ≥ 12 week lapatinib/capecitabine treatment metastatic disease . Central nervous system metastasis permit asymptomatic control minimal steroid requirement document nonprogressing study entry . Negative urine pregnancy test within 7 day prior registration premenopausal patient Baseline LVEF ≥50 % measure echocardiogram multiple gated acquisition scan ( MUGA ) scan Adequate hematopoietic function : Absolute granulocyte count ≥1,500/mm3 , platelet≥100,000/mm3 , hemoglobin≥9g/mm3 Adequate hepatic function : total bilirubin ≤1.5mg/dL , AST/ALT≤2 x upper normal limit ( UNL ) , alkaline phosphatase ≤2.5 x UNL , case bone metastases alkaline phosphatase ≤5 x UNL Adequate renal function : Serum creatinine ≤1.5mg/dL Ability understand comply protocol study period Patients sign write informed consent study entry Pregnant lactate woman woman childbearing potential , include woman whose last menstrual period ,12 month ago ( unless surgically sterile ) unable unwilling use adequate contraceptive measure study treatment period . Patients receive vinorelbine treatment metastatic setting . Patients receive 3 line prior antiHER2 therapy metastatic setting Patients history cancer situ uterine cervix cancer nonmelanotic skin cancer Patients GI tract disease result inability take oral medication , malabsorption syndrome , requirement IV alimentation , prior surgical procedure affect absorption , uncontrolled GI disease ( e.g. , Crohn 's disease , ulcerative colitis ) current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) Concurrent disease serious medical disorder , Serious cardiac illness : History document congestive heart failure ( CHF ) systolic dysfunction ( LVEF &lt; 50 % ) Highrisk uncontrolled arrhythmia ( ventricular tachycardia , highgrade atrioventricular ( AV ) block , supraventricular arrhythmia , prolong correct QT ( QTc ) adequately ratecontrolled ) Angina pectoris require antianginal medication Clinically significant valvular heart disease Evidence transmural infarction ECG Poorly control hypertension ( e.g . systolic &gt; 180mm Hg diastolic &gt; 100mm Hg ) know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study agent excipients .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Lapatinib</keyword>
	<keyword>Vinorelbine</keyword>
</DOC>